Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trialChristoph Röllig, Gerhard Ehninger, Carsten Müller‐Tidow et al.|The Lancet Oncology|2015Cited by 402
DNMT3A mutations in exon 23 are associated with improved survival in AML patients treated with Azacytidine plus standard chemotherapyPetra Tschanter, Carsten Müller‐Tidow, Utz Krug et al.|Kölner Universitäts PublikationsServer (Universität zu Köln)|2015Cited by 0